Collection

Early access to medicines scheme (EAMS): scientific opinions

Information on granted EAMS scientific opinions, including the public assessment report and treatment protocols.

Published 3 June 2015
Last updated 2 January 2018 + show all updates
  1. Amended to add the positive scientific opinion for emicizumab for routine prophylaxis of bleeding episodes in patients, aged 1 year and over, with haemophilia A with factor VIII inhibitors
  2. Added Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies to current EAMS opinions.
  3. Removed Dupilumab (for severe atopic dermatitis) from current EAMS as this product received a marketing authorisation from the European Commission.
  4. Link to the EAMS Scientific Opinion for Alectinib has been added to the page.
  5. New EAMS scientific opinion for Raxone added to the collections page.
  6. New EAMS scientific opinion for Oxervate added to the page.
  7. Added EAMS scientific opinion: Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (HCV) infection in adults
  8. EAMS for Dupilumab published
  9. SO for pembrolizumab for non-small cell lung cancer removed from current EAMS list.
  10. New EAMS positive scientific opinion
  11. Nivolumab to treat a type of cancer of the Lymph system - the Scientific Opinion has now expired due to a positive EC decision
  12. Added link to the scientific opinion: venetoclax for the treatment of chronic lymphocytic leukaemia (CLL)
  13. Added: Early access to medicines scheme (EAMS) scientific opinion: osimertinib (AZD9291) 40 and 80mg film-coated tablets
  14. New EAM issued to Novartis for sacubitril-valsartan
  15. First published.